Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content


Hot Topics of the Day|PHGKB
Search PHGKB:

Archive

Hot Topics of the Day are picked by experts to capture the latest information and publications on public health genomics and precision health for various diseases and health topics. Sources include published scientific literature, reviews, blogs and popular press articles.

Sign up MyPHGKB to receive the daily hot topic email alert.

Search Archive:
Archived Hot Topics of the Day By Date
43 hot topic(s) found with the query "Endometrial cancer"

The English National Lynch Syndrome Transformation Project
Brit Soc Gastro, July 14, 2023 (Posted: Jul 16, 2023 9AM)

Lynch syndrome (LS) affects approximately 1 in 400 individuals and predisposes to multiple cancers including colorectal, endometrial, gastric, small bowel, cholangiocarinoma and other tumors. Although a common condition, it is estimated that only 5% of patients with LS are known in the UK. There is consistent evidence of the cost-effectiveness and clinical benefit of a structured diagnostic pathway in patients with LS following a diagnosis of cancer linked to cascade testing in families. NICE DG27 and DG42 guidelines recommend universal testing of newly diagnosed colorectal and endometrial cancer for Lynch syndrome (LS), however there is strong evidence of variation in delivery of these guidelines by clinical services.

CXCR3 predicts the prognosis of endometrial adenocarcinoma.
He Dong et al. BMC medical genomics 2023 2 (1) 20 (Posted: Feb 09, 2023 6AM)

Relevance of Molecular Profiling in Patients With Low-Grade Endometrial Cancer.
Vrede Stephanie W et al. JAMA network open 2022 12 (12) e2247372 (Posted: Dec 20, 2022 8AM)

Is tumor molecular profile associated with outcomes among patients with low-grade endometrial cancer? In this retrospective multicenter cohort study of 393 patients, outcomes for patients with low-grade endometrial cancer were not associated with molecular subgroup. These findings do not support routine molecular profiling in patients with low-grade endometrial cancer.

Integration of Molecular Data in the Prognostic Stratification and Management of Endometrial Carcinoma
A Raffone et al, J Per Med, December 18, 2022 (Posted: Dec 18, 2022 9AM)

In the last years, the TCGA-based molecular classifier have been progressively integrated in the management of endometrial carcinoma. While molecular assays are increasingly available across pathology laboratories, the additional costs will expectedly be compensated by a reduction in overtreatments and a prevention of recurrences. The additional time might be shortened by assessing molecular markers on biopsy specimens.

Development and evaluation of polygenic risk scores for prediction of endometrial cancer risk in European women.
Bafligil Cemsel et al. Genetics in medicine : official journal of the American College of Medical Genetics 2022 6 (Posted: Jun 17, 2022 8AM)

We developed PRSs from SNVs identified from a systematic review of published studies and suggestive SNVs from the Endometrial Cancer Association Consortium. These were tested in an independent study of 555 surgically-confirmed endometrial cancer cases and 1202 geographically-matched controls from Manchester, United Kingdom and validated in 1676 cases and 116,960 controls from the UK Biobank (UKBB).

Lynch syndrome; towards more personalized management?
J Llach et al, Best Practice & Research Clinical Gastroenterology, March 2022 (Posted: Apr 20, 2022 9AM)

Lynch syndrome is the most common inherited cause of colorectal (lifetime risk up to 70%) and endometrial cancer. The diagnosis of Lynch syndrome facilitates preventive measures aimed at reducing the incidence and mortality of cancer. Colonoscopic surveillance for colorectal cancer, aspirin, and prophylactic hysterectomy and bilateral salpo-oopherectomy for endometrial and/or ovarian cancer have demonstrated to effectively reduce cancer mortality in this population. However, the lifetime risk of each cancer in people with Lynch syndrome is gene-specific and may be modified by environmental factors. Furthermore, the benefits of surveillance strategies need to be balanced against the risk of over-diagnosis and be supported by evidence of improved outcomes

Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits.
Schrijver Lieske H et al. Journal of the National Cancer Institute 2022 1 (Posted: Jan 29, 2022 11AM)

To help BRCA1/2 mutation carriers make informed decisions regarding use of combined-type oral contraceptive preparation (COCP), absolute risk-benefit estimates are needed for COCP-associated cancer. For a hypothetical cohort of 10,000 women, we calculated the increased or decreased cumulative incidence of COCP-associated (breast/ovarian/endometrial) cancer, examining 18 scenarios with differences in duration and timing of COCP use, uptake of prophylactic surgeries and menopausal hormone therapy.

Up-Front Multigene Panel Testing for Cancer Susceptibility in Patients With Newly Diagnosed Endometrial Cancer: A Multicenter Prospective Study
MD Levine et al, JCO Precision Oncology, October 2021 (Posted: Dec 02, 2021 8AM)

Likely pathogenic variants or PVs were identified in 97 of 961 women (10.1%). Lynch syndrome was diagnosed in 29 of 961 patients (3%; 95% CI, 2.1 to 4.3), with PVs in PMS2 most frequent. MGPT revealed nine patients with LS in addition to the 20 identified through routine tumor-based screening. BRCA1 and BRCA2 PVs were found in 1% (10 of 961; 95% CI, 0.6 to 1.9) of patients and that group was significantly enriched for type II ECs.

PMS2 is the most frequently mutated Lynch syndrome (LS) gene in women with endometrial cancer (EC): what is the role that low penetrance LS genes play in EC?
M Levine et al, Obs Gyn, August 2021 (Posted: Aug 22, 2021 7AM)

This is the largest cohort of prospectively enrolled EC patients to undergo germline genetic testing in an unselected manner, irrespective of patient age, family history or tumor results. It shows that a majority of LS mutations in EC are in the low-penetrance genes, MSH6 and PMS2. PMS2 mutations were the most common.

Vaccine to Prevent Hereditary Cancers Nears Human Trials
S Jenks, NCI Blog, July 2021 Brand (Posted: Jul 18, 2021 7AM)

One of the first-ever vaccines for the prevention of colorectal and other cancers in patients at high genetic risk for these malignancies is expected to start its early phase safety and immunogenicity trial in the first quarter of 2022, according to investigators. Although still in the design phase, the study will test a neoantigen-based vaccine against Lynch syndrome, a common hereditary condition that carries a 70-80% lifetime risk for colorectal cancer. The syndrome also raises the risk for developing endometrial cancer and several other cancers, often before age 50 years.

FDA Approves Immunotherapy for Endometrial Cancer with Specific Biomarker- Approval is for recurrent or advanced mismatch repair deficient (dMMR) endometrial cancer
FDA, April 22, 2021 (Posted: Apr 23, 2021 9AM)

the U.S. Food and Drug Administration granted accelerated approval to Jemperli (dostarlimab) for treating patients with recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing chemotherapy and whose cancers have a specific genetic feature known as dMMR (which contain abnormalities that affect the proper repair of DNA inside the cell), as determined by an FDA-approved test.

Stakeholders’ views of integrating universal tumour screening and genetic testing for colorectal and endometrial cancer into routine oncology
ER O'Shea et al, JHG, April 2021 (Posted: Apr 03, 2021 7AM)

The majority of respondents saw the relative advantage of aligning GT to abnormal universal tumor screening (UTS) results. Both OHP and GHP’s indicated embedding a genetic counsellor in oncology or having a genetics point of contact to support integrating of GT through UTS as favorable interventions. I

Endometrial Cancer.
Lu Karen H et al. The New England journal of medicine 2020 Nov (21) 2053-2064 (Posted: Nov 20, 2020 8AM)

Identification of the Lynch syndrome in patients with endometrial cancer has become increasingly important, since immune checkpoint blockade has been approved for the treatment of advanced disease with high microsatellite instability. Another factor favoring identification of patients with the Lynch syndrome is that they are at increased risk for colon cancer.

Testing strategies for Lynch syndrome in people with endometrial cancer
NICE, October 28, 2020 (Posted: Oct 28, 2020 9AM)

Offer testing for Lynch syndrome to people who are diagnosed with endometrial cancer. Use immunohistochemistry (IHC) to identify tumors with mismatch repair (MMR) deficiency. Healthcare professionals should inform people about the possible implications of test results for both themselves and their relatives, and give support and information. Discussion of genetic testing and obtaining consent should be done by a healthcare professional with appropriate training.

Development and Validation of a Serum Metabolomic Signature for Endometrial Cancer Screening in Postmenopausal Women
J Troisi et al, JAMA Network Open, September 28, 2020 (Posted: Sep 29, 2020 8AM)

Is combining the blood metabolomic signature of endometrial carcinoma with an ensemble machine learning algorithm a useful system for screening test for endometrial cancer? In this study of 1550 postmenopausal women, the proposed screening test correctly identified all 16 women with endometrial cancer, with 2 false-positive results and 0 false-negative results.

Comparison of two Lynch screening strategies in endometrial cancer in a California health system.
Lentz Scott E et al. Gynecologic oncology 2020 May (Posted: May 12, 2020 4PM)

A Patient’s Guide to Endometrial Cancer-This cancer is on the rise. But early detection saves lives.
MO Shroeder, US News, October 4, 2019 (Posted: Oct 05, 2019 9AM)

Risk factors for this cancer include: obesity, diabetes, having close relatives like a parent or sibling who have endometrial cancer or colorectal cancer, and a genetic condition called Lynch syndrome. Having Lynch syndrome greatly increases a woman’s risk of developing endometrial cancer, and other cancers like colon and ovarian cancer

Will screening for endometrial cancer soon be routine?
Contemorary Ob/Gyn, August 14, 2019 (Posted: Aug 16, 2019 8AM)

Clinical actionability of molecular targets in endometrial cancer.
Urick Mary Ellen et al. Nature reviews. Cancer 2019 Aug (Posted: Aug 09, 2019 8AM)

This review summarizes the overarching molecular features of endometrial cancers and highlights recent studies assessing the potential clinical utility of specific molecular features for early detection, disease risk stratification and directing targeted therapies

Universal endometrial cancer tumor typing: How much has immunohistochemistry, microsatellite instability, and MLH1 methylation improved the diagnosis of Lynch syndrome across the population?
Kahn Ryan M et al. Cancer 2019 May (Posted: Jun 05, 2019 9AM)

Systematic characterization of germline variants from the DiscovEHR study endometrial carcinoma population
JE Miller et al, BMC Medical Genomics, May 2019 (Posted: May 05, 2019 0PM)

Genome-wide association studies of endometrial cancer: Latest developments and future directions.
O'Mara Tracy A et al. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2019 Apr (Posted: May 05, 2019 0PM)

Clinical and Cost Effectiveness of Two “New” Lynch Syndrome Case Finding Protocols in Endometrial Cancer Population Contrasted with the IHC-based Protocol
JM Gudgeon et al, BioRXIV, April 18, 2019 (Posted: Apr 21, 2019 6PM)

DNA Mismatch Repair Protein Immunohistochemistry and MLH1 Promotor Methylation Testing for Practical Molecular Classification and the Prediction of Prognosis in Endometrial Cancer.
Kim Jisup et al. Cancers 2018 Aug 10(9) (Posted: Aug 29, 2018 10AM)

The prevalence of Lynch syndrome in women with endometrial cancer: a systematic review protocol.
Ryan Neil A J et al. Systematic reviews 2018 Aug 7(1) 121 (Posted: Aug 22, 2018 11AM)

Identification of nine new susceptibility loci for endometrial cancer
TA O'Mara et al, Nature COmm, AUgust 9, 2018 (Posted: Aug 09, 2018 10AM)

Missed opportunities: Genetic counseling and testing among an ethnically diverse cohort of women with endometrial cancer.
Lee Jessica et al. Gynecologic oncology 2018 Aug (Posted: Aug 07, 2018 8AM)

The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses.
McAlpine Jessica et al. The Journal of pathology 2018 Apr (5) 538-549 (Posted: Jun 29, 2018 10AM)

Evolving Roles of Histologic Evaluation and Molecular/Genomic Profiling in the Management of Endometrial Cancer.
Murali Rajmohan et al. Journal of the National Comprehensive Cancer Network : JNCCN 2018 Feb (2) 201-209 (Posted: Jun 29, 2018 10AM)

Lynch Syndrome Testing Results Conflict Among Women with Endometrial Cancer
J Skarzynski, Cure, Apr 1, 2018 (Posted: Apr 03, 2018 9AM)

Family history of cancer predicts endometrial cancer risk independently of Lynch Syndrome: Implications for genetic counselling.
Johnatty Sharon E et al. Gynecologic oncology 2017 Aug (Posted: Aug 23, 2017 9AM)

Importance of PCR-based Tumor Testing in the Evaluation of Lynch Syndrome-associated Endometrial Cancer.
Bruegl Amanda S et al. Advances in anatomic pathology 2017 Aug (Posted: Aug 23, 2017 9AM)

Isolated Loss of PMS2 Immunohistochemical Expression is Frequently Caused by Heterogenous MLH1 Promoter Hypermethylation in Lynch Syndrome Screening for Endometrial Cancer Patients.
Kato Aya et al. The American journal of surgical pathology 2016 Jun 40(6) 770-6 (Posted: Jul 26, 2017 9AM)

Clinical challenges associated with universal screening for Lynch Syndrome associated endometrial cancer.
Bruegl Amanda et al. Cancer prevention research (Philadelphia, Pa.) 2016 Dec (Posted: Dec 21, 2016 10AM)

Towards value-based universal Lynch syndrome identification in endometrial cancer patients.
Dottino Joseph A et al. Gynecologic oncology 2016 Dec 143(3) 451-452 (Posted: Nov 21, 2016 1PM)

Cost-effectiveness of routine screening for Lynch syndrome in endometrial cancer patients up to 70years of age.
Goverde Anne et al. Gynecologic oncology 2016 Oct (Posted: Nov 02, 2016 10AM)

Genetic screening in young women diagnosed with endometrial cancer.
Pecorino Basilio et al. Journal of gynecologic oncology 2016 Sep e4 (Posted: Oct 05, 2016 2PM)

ECGene: A Literature-Based Knowledgebase of Endometrial Cancer Genes.
Zhao Min et al. Human mutation 2015 Dec (Posted: Dec 29, 2015 11AM)

Fast facts on uterine and endometrial cancer [PDF 622.85 KB]
Brand (Posted: Sep 11, 2015 9AM)

Symposium on advances in endometrial cancer epidemiology and biology.
Olson Sara H et al. Gynecol. Oncol. 2015 Sep (3) 497-500 (Posted: Sep 10, 2015 2PM)

Screening for Lynch syndrome among patients with newly diagnosed endometrial cancer: a comprehensive review.
Aguirre Elena et al. Tumori 2015 Jul 15. (0) 0 (Posted: Jul 30, 2015 8AM)

Female Hormonal Factors and the Risk of Endometrial Cancer in Lynch Syndrome.
Dashti Seyedeh Ghazaleh et al. JAMA 2015 Jul 7. (1) 61-71 (Posted: Jul 09, 2015 3PM)

Establishing UniversalLynch Syndrome Screening in the Community
Brand (Posted: Jan 11, 2014 11AM)

Lynch Syndrome Over 1.2 million individuals in the U.S. have Lynch Syndrome Inherited condition that causes high risks forcolorectal cancer, endometrial cancer and other cancers Preventable cancers with early and more frequent screening 95% of affected individuals do not know they haveLynch Syndrome


Disclaimer: Articles listed in Hot Topics of the Day are selected by Public Health Genomics Branch to provide current awareness of the scientific literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the Clips, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
TOP